Subbiah V, Iannotti NO, Gutierrez M, Smith DC, et al. FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies. Ann Oncol 2022;33:522-533.
PMID: 35176457